(CI) Cigna - Overview
Stock: Insurance, Pharmacy, PBM, Medicare, Dental
EPS (Earnings per Share)
Revenue
Dividends
| Dividend Yield | 2.03% |
| Yield on Cost 5y | 3.17% |
| Yield CAGR 5y | 10.85% |
| Payout Consistency | 88.9% |
| Payout Ratio | 20.4% |
| Risk 5d forecast | |
|---|---|
| Volatility | 37.7% |
| Relative Tail Risk | -24.2% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | 0.19 |
| Alpha | -1.79 |
| Character TTM | |
|---|---|
| Beta | 0.196 |
| Beta Downside | 0.147 |
| Drawdowns 3y | |
|---|---|
| Max DD | 32.10% |
| CAGR/Max DD | 0.04 |
Description: CI Cigna January 27, 2026
The Cigna Group (NYSE:CI) operates two primary segments: Evernorth Health Services, which delivers pharmacy-benefit management, specialty pharmacy, home-delivery, and broader care-coordination solutions to insurers, employers, and government entities; and Cigna Healthcare, which provides medical, pharmacy, behavioral health, dental, Medicare Advantage/Supplement/Part D, and individual health plans in the U.S. and select international markets. The firm also offers corporate life-insurance contracts and stop-loss coverage, distributing products through brokers, direct employer channels, and public exchanges. The company, founded in 1792 and rebranded in February 2023, is headquartered in Bloomfield, Connecticut.
Key recent metrics (Q4 2023/2024 FY): revenue of $19.2 billion, a 5.2 % YoY increase driven by higher enrollment in Medicare Advantage (+8 % member growth) and expanding pharmacy-benefit contracts; operating margin of 8.6 % after a 120 bps improvement in medical loss ratio to 84.5 %; and cash flow from operations of $2.1 billion, supporting a $1.5 billion share-repurchase program. Sector-wide, the aging U.S. population and rising Medicare enrollment are expected to lift health-plan premiums by 3-4 % annually, while inflationary pressure on prescription-drug costs remains a primary cost driver for insurers.
For a deeper quantitative view, consider reviewing ValueRay’s detailed financial models and scenario analyses.
Piotroski VR‑10 (Strict, 0-10) 6.0
| Net Income: 5.96b TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.05 > 0.02 and ΔFCF/TA 1.45 > 1.0 |
| NWC/Revenue: -3.31% < 20% (prev -3.69%; Δ 0.37% < -1%) |
| CFO/TA 0.06 > 3% & CFO 8.66b > Net Income 5.96b |
| Net Debt (24.42b) to EBITDA (12.17b): 2.01 < 3 |
| Current Ratio: 0.84 > 1.5 & < 3 |
| Outstanding Shares: last quarter (265.9m) vs 12m ago -4.26% < -2% |
| Gross Margin: 9.45% > 18% (prev 0.11%; Δ 934.6% > 0.5%) |
| Asset Turnover: 176.4% > 50% (prev 158.5%; Δ 17.85% > 0%) |
| Interest Coverage Ratio: 6.90 > 6 (EBITDA TTM 12.17b / Interest Expense TTM 1.38b) |
Altman Z'' 1.31
| A: -0.06 (Total Current Assets 48.87b - Total Current Liabilities 57.98b) / Total Assets 155.88b |
| B: 0.28 (Retained Earnings 43.52b / Total Assets 155.88b) |
| C: 0.06 (EBIT TTM 9.53b / Avg Total Assets 155.88b) |
| D: 0.36 (Book Value of Equity 41.18b / Total Liabilities 114.64b) |
| Altman-Z'' Score: 1.31 = BB |
Beneish M -2.95
| DSRI: 0.90 (Receivables 24.07b/24.07b, Revenue 274.95b/247.12b) |
| GMI: 1.11 (GM 9.45% / 10.51%) |
| AQI: 1.0 (AQ_t 0.68 / AQ_t-1 0.68) |
| SGI: 1.11 (Revenue 274.95b / 247.12b) |
| TATA: -0.02 (NI 5.96b - CFO 8.66b) / TA 155.88b) |
| Beneish M-Score: -2.95 (Cap -4..+1) = A |
What is the price of CI shares?
Over the past week, the price has changed by +8.42%, over one month by +5.54%, over three months by +14.68% and over the past year by +2.61%.
Is CI a buy, sell or hold?
- StrongBuy: 13
- Buy: 6
- Hold: 6
- Sell: 0
- StrongSell: 0
What are the forecasts/targets for the CI price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 328.8 | 11.7% |
| Analysts Target Price | 328.8 | 11.7% |
| ValueRay Target Price | 302.4 | 2.7% |
CI Fundamental Data Overview February 09, 2026
P/E Forward = 9.5877
P/S = 0.2838
P/B = 1.8406
P/EG = 0.5882
Revenue TTM = 274.95b USD
EBIT TTM = 9.53b USD
EBITDA TTM = 12.17b USD
Long Term Debt = 28.94b USD (from longTermDebt, last fiscal year)
Short Term Debt = 3.04b USD (from shortTermDebt, last fiscal year)
Debt = 31.97b USD (from shortLongTermDebtTotal, last fiscal year)
Net Debt = 24.42b USD (from netDebt column, last fiscal year)
Enterprise Value = 102.44b USD (78.01b + Debt 31.97b - CCE 7.55b)
Interest Coverage Ratio = 6.90 (Ebit TTM 9.53b / Interest Expense TTM 1.38b)
EV/FCF = 13.77x (Enterprise Value 102.44b / FCF TTM 7.44b)
FCF Yield = 7.26% (FCF TTM 7.44b / Enterprise Value 102.44b)
FCF Margin = 2.70% (FCF TTM 7.44b / Revenue TTM 274.95b)
Net Margin = 2.17% (Net Income TTM 5.96b / Revenue TTM 274.95b)
Gross Margin = 9.45% ((Revenue TTM 274.95b - Cost of Revenue TTM 248.97b) / Revenue TTM)
Gross Margin QoQ = 7.66% (prev 8.52%)
Tobins Q-Ratio = 0.66 (Enterprise Value 102.44b / Total Assets 155.88b)
Interest Expense / Debt = 1.05% (Interest Expense 335.0m / Debt 31.97b)
Taxrate = 24.25% (395.0m / 1.63b)
NOPAT = 7.22b (EBIT 9.53b * (1 - 24.25%))
Current Ratio = 0.84 (Total Current Assets 48.87b / Total Current Liabilities 57.98b)
Debt / Equity = 0.78 (Debt 31.97b / totalStockholderEquity, last fiscal year 41.03b)
Debt / EBITDA = 2.01 (Net Debt 24.42b / EBITDA 12.17b)
Debt / FCF = 3.28 (Net Debt 24.42b / FCF TTM 7.44b)
Total Stockholder Equity = 40.82b (last 4 quarters mean from totalStockholderEquity)
RoA = 3.82% (Net Income 5.96b / Total Assets 155.88b)
RoE = 14.59% (Net Income TTM 5.96b / Total Stockholder Equity 40.82b)
RoCE = 13.67% (EBIT 9.53b / Capital Employed (Equity 40.82b + L.T.Debt 28.94b))
RoIC = 9.96% (NOPAT 7.22b / Invested Capital 72.50b)
WACC = 4.94% (E(78.01b)/V(109.99b) * Re(6.64%) + D(31.97b)/V(109.99b) * Rd(1.05%) * (1-Tc(0.24)))
Discount Rate = 6.64% (= CAPM, Blume Beta Adj.) -> floored to rf + 0.7*ERP = 7.95%
Shares Correlation 3-Years: -100.0 | Cagr: -4.98%
[DCF Debug] Terminal Value 86.88% ; FCFF base≈6.54b ; Y1≈6.92b ; Y5≈8.21b
Fair Price DCF = 831.1 (EV 243.40b - Net Debt 24.42b = Equity 218.98b / Shares 263.5m; r=5.90% [WACC]; 5y FCF grow 6.47% → 2.90% )
EPS Correlation: 78.55 | EPS CAGR: 8.21% | SUE: 0.35 | # QB: 0
Revenue Correlation: 97.74 | Revenue CAGR: 14.23% | SUE: 1.78 | # QB: 11
EPS next Quarter (2026-03-31): EPS=7.37 | Chg30d=+0.125 | Revisions Net=-2 | Analysts=18
EPS current Year (2026-12-31): EPS=30.27 | Chg30d=-0.191 | Revisions Net=-1 | Growth EPS=+1.5% | Growth Revenue=+1.7%
EPS next Year (2027-12-31): EPS=33.41 | Chg30d=-0.093 | Revisions Net=-1 | Growth EPS=+10.4% | Growth Revenue=+7.1%